Document Report Card
Basic Information
ID: ALA4630904
Title: Data for DCP probe BI 207127
Authors: SGC Frankfurt
Abstract: SGC Frankfurt donated chemical probe project: BI 207127 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20207127. Control: BI-7656. References: 1. LaPlante, Steven R., Michael Bös, Christian Brochu, Catherine Chabot, René Coulombe, James R. Gillard, Araz Jakalian, Martin Poirier, Jean Rancourt, Timothy Stammers, Bounkham Thavonekham, Pierre L. Beaulieu, George Kukolj, and Youla S. Tsantrizos. 2014. ‘Conformation-Based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127)’. Journal of Medicinal Chemistry 57(5):1845–54. doi: 10.1021/jm4011862. PMID: 24159919. 2. Sarrazin, Christoph, Michael Manns, Jose Luis Calleja, Javier Garcia-Samaniego, Xavier Forns, Renee Kaste, Xiaofei Bai, Jing Wu, and Jerry O. Stern. 2016. ‘HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment’. PloS One 11(12):e0168544. doi: 10.1371/journal.pone.0168544. PMID: 28030579 (Secondary paper). 3. Zeuzem, Stefan, Parvez Mantry, Vicente Soriano, Robert J. Buynak, Jean-François Dufour, Paul J. Pockros, David Wright, Peter Angus, Maria Buti, Jerry O. Stern, Werner Kadus, Richard Vinisko, Wulf Böcher, and Federico J. Mensa. 2016. ‘Short Article: Faldaprevir, Deleobuvir and Ribavirin in IL28B Non-CC Patients with HCV Genotype-1a Infection Included in the SOUND-C3 Phase 2b Study’. European Journal of Gastroenterology & Hepatology 28(8):923–26. doi: 10.1097/MEG.0000000000000649. PMID: 27140229 (Secondary paper). 4. Larrey, Dominique, Ansgar W. Lohse, Christian Trepo, Jean-Pierre Bronowicki, Keikawus Arastéh, Marc Bourlière, Jose Luis Calleja, Jerry O. Stern, Gerhard Nehmiz, Nasri Abdallah, Kristi L. Berger, Martin Marquis, Jürgen Steffgen, George Kukolj, and BI 207127 Study Group. 2013. ‘Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C’. Antimicrobial Agents and Chemotherapy 57(10):4727–35. doi: 10.1128/AAC.00565-13. PMID: 23856779 (Secondary paper).